Division of Vascular Surgery, Department of Surgery, Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
J Vasc Access. 2022 May;23(3):430-435. doi: 10.1177/1129729821998526. Epub 2021 Mar 8.
This retrospective study evaluates the clinical outcomes of two heparin-bonded expanded polytetrafluoroethylene grafts, PROPATEN and ACUSEAL (W. L. Gore & Associates, Flagstaff, AZ, USA), for forearm loop vascular access.
We prospectively collected data on 60 patients who had undergone arteriovenous graft of the forearm loop type between January 2015 and December 2019. The primary endpoints were graft primary, assisted primary, and secondary patency rates. Secondary endpoints were time to first cannulation and postoperative complications.
We enrolled 36 patients in the PROPATEN group (Group P) and 24 in the ACUSEAL group (Group A). All procedures were successful without any 30-day mortality. The median times to first cannulation were 16.5 days and 3 days in Groups P and A, respectively ( < 0.001). Mean follow-up periods were 13.4 ± 14.5 and 17.3 ± 9.3 months, respectively. Primary patency rates were 81% and 64%, respectively, at 6 months, and 60% and 40%, respectively, at 12 months ( = 0.008). Assisted primary patency rates were 96% and 83% at 6 months, 91% and 73% at 12 months, and 81% and 35% at 24 months ( = 0.044). Secondary patency rates were 96% and 81% at 12 months, and 87% and 62% at 24 months ( = 0.207). As a remote-period complication, disruption of the luminal layer of the graft was observed in two patients (4.2%) in Group A due to puncture and thrombectomy.
Although the ACUSEAL graft offers the advantage of early cannulation, its primary and assisted primary patency outcomes were inferior to those of the PROPATEN graft. It is important for physicians to be aware of the different characteristics of each graft to select the best option for each patient.
本回顾性研究评估了两种肝素结合膨胀聚四氟乙烯移植物(W. L. Gore & Associates,Flagstaff,AZ,USA)在前臂环血管通路中的临床效果,这两种移植物分别是 PROPATEN 和 ACUSEAL。
我们前瞻性收集了 2015 年 1 月至 2019 年 12 月期间接受前臂环式动静脉移植物的 60 例患者的数据。主要终点是移植物的初始通畅率、辅助初始通畅率和次级通畅率。次要终点是首次穿刺时间和术后并发症。
我们将 36 例患者纳入 PROPATEN 组(P 组),24 例患者纳入 ACUSEAL 组(A 组)。所有手术均成功,无 30 天内死亡。P 组和 A 组的首次穿刺时间中位数分别为 16.5 天和 3 天( < 0.001)。平均随访时间分别为 13.4 ± 14.5 个月和 17.3 ± 9.3 个月。6 个月时,初始通畅率分别为 81%和 64%,12 个月时分别为 60%和 40%( = 0.008)。辅助初始通畅率分别为 96%和 83%,6 个月时分别为 91%和 73%,12 个月时分别为 81%和 35%( = 0.044)。次级通畅率分别为 96%和 81%,12 个月时分别为 87%和 62%( = 0.207)。在 12 个月的远程随访期,A 组有 2 例(4.2%)患者因穿刺和血栓切除术导致移植物管腔层破裂。
虽然 ACUSEAL 移植物具有早期穿刺的优势,但它的初始和辅助初始通畅率均低于 PROPATEN 移植物。医生了解每种移植物的不同特点,为每位患者选择最佳的移植物非常重要。